Russian scientists are exploring the use of bacteria for targeted drug delivery

22 August 2018

GMP News

Russian physicists will be able to control the movement of bacteria for the treatment of cardiovascular diseases. For this purpose in collaboration with microbiologists, they established a laboratory at the Moscow Institute of Physics and Technology, according to information from the Joint Institute for High Temperatures (JIHT) of the Russian Academy of Sciences.

“JIHT opens at Moscow Institute of Physics and Technology (MIPT) the laboratory of active media and systems in collaboration with the Gamaleya Research Institute of Epidemiology and Microbiology. In interaction with microbiologists JIHT scientists plan to set up experiments with bacterial cultures that behave like active particles in some settings,” the report says.

As scientists have explained, in medicine, research in the field of active particles is associated with the possibility of targeted drug delivery – for example to the tumor area for its subsequent irradiation. Active particles can also eliminate atherosclerotic plaques that build up in the walls of blood vessels.

“We are talking about the use and transformation of energy from an external source into the energy of motion: if we control this mechanism, then we control the motion of the particles and can make them move in a required direction – for example, along blood vessels under control of magnetic field or particles with magnetic properties,” commented Oleg Petrovdirector of theJIHT RAS.

In his opinion, the work of the laboratory will bring to a new level both interdisciplinary research at the intersection of physics and microbiology, and interdepartmental interaction in new scientific fields.


Previous publication Next publication

Media Center

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

  • 18 October 2018

    Russia emerges as frontrunner in global fight against tuberculosis

    Russia has turned out to be the world’s most successful tuberculosis fighter, Russian Health Minister Veronika Skvortsova stated  during the interview with the Rossiya-24 channel. "We are the global leader according to the pace in solving this issue," she noted, adding, "all countries acknowledge Russia’s foremost role here."

  • 17 October 2018

    Scientists developed new tool for open exchange of biomaterials

    A new easy-to-use legal tool that enables open exchange of biological materials was launched. The OpenMTA is a Material Transfer Agreement (MTA) designed to support openness, sharing and innovation in global biotechnology. Material Transfer Agreements (MTAs) provide the legal frameworks within which research organisations define terms and conditions for sharing their materials – everything from DNA molecules to plant seeds to patient samples.

  • 16 October 2018

    The First FDA-approved Digital Pill — What It Means for Pharma

    Last year, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill that is integrated with an ingestible sensor that captures information about whether the patient has complied with her medication regimen. A patient ingests the pill and it sends the data to a patch worn on her torso, which adds various physiologic measures. From there the information is wirelessly sent to a mobile phone app, allowing both the patient and her physician to track how the patient is using and responding to her medication.

Read more